Cardiome’s Kynapid trial suspended

Cardiome Pharma’s (NASDAQ: CRME; TSX:COM) co-development partner, Astellas Pharma U.S., has suspended patient enrolment in the ACT 5 study of Kynapid after an unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received the drug. The trial’s Data Safety Monitoring Board has reviewed the case and recommended the trial [...]

EU approves Cardiome’s Brinavess for IV

Cardiome Pharma’s (NASDAQ: CRME; TSX:COM) intravenous formulation of Brinavess has received marketing approval in the European Union, Iceland and Norway for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Patrick Magri, senior vice president, general manager, Cardiovascular Franchise, Merck (NYSE:MRK), said “we welcome this important milestone in our collaboration with [...]

Cardiome drug clears European committee

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing approval for Cardiome Pharma’s (TSX:COM; NASDAQ:CRME) vernakalant, an investigational intravenous formulation for the conversion of atrial fibrillation to normal heart rhythm in adults. Granting of marketing authorization by the European Commission is expected later this year and will apply [...]